---
title: "Neumora Therapeutics, Inc. (NMRA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/NMRA.US.md"
symbol: "NMRA.US"
name: "Neumora Therapeutics, Inc."
industry: "制药"
---

# Neumora Therapeutics, Inc. (NMRA.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.neumoratx.com](https://www.neumoratx.com) |

## Company Profile

Neumora Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发针对脑部疾病、神经精神障碍和神经退行性疾病的治疗方案。该公司正在开发 navacaprant（NMRA-140），这是一种新型的每日一次口服κ阿片受体拮抗剂，目前正在进行针对重度抑郁症的三期临床试验。它还在开发 NMRA-511，该药物目前正在针对阿尔茨海默病相关的激动症状的患者进行一期临床试验。此外，该公司的临床前产品包括用于治疗精神分裂症的 NMRA-NMDA 和 NMRA-M4R；用于治疗肌萎缩侧索硬化症的 CK1d 抑制剂项目 NMRA-CK1d；用于治疗某些神经退行性疾病的 NMRA-NLRP...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.44 | 139/257 | - | - | - |
| PB | 4.36 | 132/257 | 2.59 | 1.45 | 0.56 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-19T05:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 56% |
| Overweight | 2 | 22% |
| Hold | 1 | 11% |
| Underweight | 1 | 11% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.39 |
| Highest Target | 18.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/NMRA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/NMRA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/NMRA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.